Filing Details
- Accession Number:
- 0001181431-11-058855
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-12-05 19:48:53
- Reporting Period:
- 2011-12-01
- Filing Date:
- 2011-12-05
- Accepted Time:
- 2011-12-05 19:48:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1178711 | Transcept Pharmaceuticals Inc | TSPT | Pharmaceutical Preparations (2834) | 330960223 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1408920 | T Joseph Kennedy | C/O Transcept Pharmaceuticals, Inc. 1003 W. Cutting Blvd Point Richmond CA 94804 | Vp And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-12-01 | 4,150 | $2.68 | 4,150 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-12-01 | 4,150 | $8.23 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2011-12-01 | 56,666 | $3.10 | 56,666 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-12-01 | 56,666 | $8.23 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee stock option (right to buy) | Disposition | 2011-12-01 | 4,150 | $0.00 | 4,150 | $2.68 |
Common Stock | Employee stock option (right to buy) | Disposition | 2011-12-01 | 56,666 | $0.00 | 56,666 | $3.10 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
38,750 | 2021-08-24 | No | 4 | M | Direct | |
28,334 | 2019-03-12 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 12, 2011.
- The sales price reported in column 4 of Table 1 represents the weighted average sales price of the shares sold ranging from $8.52 to $8.00 per share. Upon request of the commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Fifty percent of the option vests upon approval by the U.S. Food and Drug Administration of Intermezzo (R) and the remaining fifty percent vests on the first anniversary of any such approval; provided in each case, such approval occurs no later than August 24, 2013. Approval by the U.S. Food and Drug Administration of Intermezzo (R) occurred on November 23, 2011.
- One fourth of the shares subject to the option vested on March 6, 2010 and one forty-eighth of the shares vest monthly thereafter.